RBC Capital Markets has a message for investors in Reckitt Benckiser: the stock looks cheap, but that doesn't mean it's time to buy. The bank kept its 'Sector Perform' rating on the consumer goods giant after the company's third-quarter update, even as its valuation model suggests the shares are trading below their fair value.
The decision comes after Reckitt's third-quarter results were hit by production problems at its Lysol disinfectant brand, a key product in its health and hygiene portfolio. The disruption weighed on sales and added to a pattern of unpredictable earnings that has frustrated analysts and investors alike.
What RBC is saying
RBC's price target for Reckitt stands at GBP62, based on its Adjusted Present Value (APV) model. That model, which values a company by discounting its expected future cash flows and adding the value of tax shields and other adjustments, suggests the shares are undervalued at current levels.
Yet the bank stopped short of upgrading the stock to 'Outperform'. In a note to clients, RBC argued that the bigger issue is not the valuation but the reliability of Reckitt's results. The Lysol disruption in the third quarter is the latest example of how hard it has been to forecast the company's performance, making it difficult to justify a more bullish stance.
RBC also trimmed its revenue forecasts for 2026 through 2028, reflecting the impact of the production issues and a more cautious outlook for the company's growth trajectory.
Why Reckitt's results have been hard to predict
Reckitt, which owns brands like Dettol, Nurofen, and Finish, has faced a series of challenges in recent years. Supply chain disruptions, input cost inflation, and shifting consumer demand have all contributed to volatility in its numbers. The Lysol production problem is just the latest hiccup, and it highlights how operational issues can quickly derail even well-known consumer staples.
For a company that investors often view as a defensive holding, this unpredictability is a concern. Consumer goods stocks are typically seen as stable, reliable dividend payers, but when results swing, that reputation takes a hit.
The company's sales forecast was recently trimmed as the Lysol supply crunch hit North America, a key market for the brand. That news, along with other disappointing results, has weighed on the stock and contributed to broader weakness in London's market, as seen in HSBC and Reckitt dragging London shares lower.
What it means for investors
For everyday investors, the key takeaway is that a cheap-looking stock isn't always a good buy. RBC's stance underscores the importance of looking beyond valuation metrics to consider the quality and predictability of a company's earnings.
Reckitt's situation is a reminder that even well-established consumer brands can face operational setbacks. When a company's results are hard to forecast, the risk premium investors demand tends to rise, which can keep a lid on the share price even if the numbers look attractive on paper.
Investors should also note that RBC's price target of GBP62 is not a guarantee of where the stock will go. It's an estimate based on a specific model, and models can be wrong. The bank's decision to keep a 'Sector Perform' rating suggests it sees the stock as fairly valued relative to its risks, rather than a screaming buy.
For those who already own Reckitt shares, the news is mixed. On one hand, the valuation support may offer some downside protection. On the other, the company's near-term growth prospects appear clouded by the production issues and the trimmed forecasts.
It's also worth noting that Reckitt isn't the only consumer company facing similar scrutiny. UBS recently saw a solid quarter from Estée Lauder but kept a neutral rating, and Tata Consumer saw upgrades on new brand growth. These examples show that analysts are being selective, rewarding companies with clear momentum and punishing those with operational hiccups.
The bottom line
RBC's stance on Reckitt is a classic case of 'value trap' caution. The stock may look cheap, but until the company can demonstrate more consistent results, the bank is unwilling to recommend it. For investors, the lesson is to focus on the reliability of earnings, not just the price tag.
As Reckitt works through its Lysol production issues and tries to regain its footing, the market will be watching closely. Any signs of improvement in operational stability could change the narrative, but for now, RBC's cautious tone reflects the uncertainty that surrounds the company.
